Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

Health Economics Review

Volumn 2, Issue 1, 2012, Pages 1-12

  García Ruiz, Antonio J ^a   Pérez Costillas, Lucía ^b   Montesinos, Ana C ^b   Alcalde, Javier ^a   Oyagüez, Itziar ^c   Casado, Miguel A ^c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c Pharmacoeconomics and Outcomes Research Iberia (PORIB)   (Spain)

Author keywords

Antipsychotic; Cost effectiveness; Cost utility; Relapse; Schizophrenia; Spain

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE;

ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HUMAN; MATHEMATICAL COMPUTING; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SPAIN;

EID: 84971325294     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-2-8     Document Type: Article

References (54)

1. Awad AG, Voruganti LN: The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008, 26(2):149-162.
2. Gee L, Pearce E, Jackson M: Quality of life in schizophrenia: a grounded theory approach. Health Qual Life Outcomes 2003, 1:31.
3. Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull 2004, 30(2):279-293.
4. Piccinelli M, Gomez Homen F: Gender differences in the epidemiology of affective disorders and schizophrenia. Division of Mental Health and Prevention of substance abuse. Ed World Health Organization (WHO), Geneva; 1997 [http://www.who.int/mental_health/media/en/54.pdf], [accessed on November 12th, 2010].
5. McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008, 30:67-76.
6. Messias EL, Chen CY, Eaton WW: Epidemiology of schizophrenia: review of findings and myths. Psychiatr Clin North Am 2007, 30(3):323-338.
7. Awad AG, Voruganti LN, Heslegrave RJ: Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997, 11(1):32-47.
8. Awad AG, Voruganti LN: Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 2004, 18(13):877-893.
9. Allison DB, Casey DE: Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001, 62(Suppl 7):22-31.
10. Vázquez-Barquero JL, Cuesta Nuñez MJ, de la Varga M, Herrera Castanedo S, Gaite L, Arenal A: The Cantabria first episode schizophrenia study: a summary of general findings. Acta Psychiatr Scand 1995, 91(3):156-162.
11. Tajima K, Hernández H, López-Ibor JJ, Carrasco JL, Díaz-Marsá M: Tratamientos para la esquizofrenia. Revisión crítica sobre la farmacología y mecanismos de acción de los antipsicóticos. Actas Esp Psiquiatr 2009, 37(6):330-342.
12. Ayuso-Gutiérrez JL, del Río Vega JM: Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997, 28(2-3):199-206.
13. Samalin L, Blanc O, Llorca PM: Optimizing treatment of schizophrenia to minimize relapse. Expert Rev Neurother 2010, 10(2):147-150.
14. Davies T: Psychosocial factors and relapse of schizophrenia Interventions with the families of schizophrenics can reduce relapse rates. BMJ 1994, 309:353-354.
15. Lader M: What is relapse in schizophrenia? Int Clin Psychopharmacol 1995, 9(Suppl 5):5-9.
16. Briggs A, Wild D, Lees M, Reaney M, Dursun S, Parry D, Mukherjee J: Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008, 6:105.
17. Marwaha S, Johnson S, Bebbington P, Stafford M, Angermeyer MC, Brugha T, Azorin JM, Kilian R, Hansen K, Toumi M: Rates and correlates of employment in people with schizophrenia in the UK, France and Germany. Br J Psychiatry 2007, 191:30-37.
18. NICE. National Institute for Health and Clinical Excellence. Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). 2009 [http://www.nice.org.uk], National Clinical Practice Guideline Number 82. [accessed on November 12th, 2010].
19. Martín JJ, González Mdel P: The sustainability of the Spanish National Health System. Cien Saude Colet 2011, 16(6):2773-2782.
20. Vázquez-Polo FJ, Negrín M, Cabasés JM, Sánchez E, Haro JM, Salvador-Carulla L: An analysis of the costs of treating schizophrenia in Spain: a hierarchical Bayesian approach. J Ment Health Policy Econ 2005, 8(3):153-165.
21. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, Markwick A, Lloyd H, CUtLASS team: Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007, 191:14-22.
22. Gray R, Gournay K: What can we do about acute extrapyramidal symptoms? J Psychiatr Ment Health Nurs 2000, 7(3):205-211.
23. Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003, 54(4):565-567.
24. López-Bastida J, Oliva J, Antoñanzas F, García-Altés A, Gisbert R, Mar J, Puig-Junoy J: Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010, 11(5):513-520.
25. Sacristán JA, Soto J, Reviriego J, Galende I: Farmacoeconomía: el cálculo de la eficiencia. Med Clin (Barc) 1994, 103:143-149.
26. Ortún V: 30.000 euros por AVAC. Econ Salud 2004, 17(49):1-2.
27. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL: What is an efficient health technology in Spain? Gac Sanit 2002, 16:334-343.
28. Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M: Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004, 71(1):155-165.
29. Mata Cases M, Roset Gamisans M, Badia Llach X, Antoñanzas Villar F, Ragel Alcázar J: Impacto de la diabetes mellitus tipo 2 en la calidad de vida de los pacientes tratados en las consultas de atención primaria en España. Aten Primaria 2003, 31(8):493-499.
30. Clarke P, Gray A, Holman R: Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002, 22:340-349.
31. COF Consejo General de Colegios Oficiales de Farmacéuticos: Catálogo Nacional de Especialidades; [http://www.portalfarma.com].
32. MSPS Ministerio de Sanidad y Política Social: Explotación del registro de altas CMBD del Sistema Nacional de Salud. [http://www.msc.es/estadEstudios/estadisticas/cmbd/informes/2007/Categoria_Diagnostica_Mayor(CDM)/CDM019/GRD430/GRD430.html], [accessed on April 14th, 2010].
33. Departamento de Sanidad. Gobierno Vasco: Informe análisis de impacto presupuestario Paliperidona. 2009 [http://www.osanet.euskadi.net/r85-20319/es/contenidos/informacion/farmacoeconomia/es_farma/fichas.html], [accessed on March 31st, 2011].
34. García AJ, Avila L, Gómez C, Montesinos AC: Direct cost for control of Diabetes Mellitus in a rural area. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 9th Annual European Congress Copenhaguen; 2006.
35. García AJ, Morata F: Direct sanitary cost of diabetes control in a rural area. Quality of life. World Organisation for General Medicine (WONCA); European conference Paris; 2007.
36. Real Decreto 1247/2002 de 3 de diciembre, por el que se regula la gestión del fondo de cohesión sanitaria. 2002, 290:42299-42330 [http:// www.boe.es/boe/dias/2002/12/04/pdfs/A42299-42330.pdf], BOE. [accessed on March 31st, 2011].
37. Levy E, Gabriel S, Dinet J: The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003, 1:651-659.
38. Antoñanzas F, Anton F, Echevarria I, Juarez C: Clínica y epidemiología de la insuficiencia cardiaca congestiva (ICC): Un análisis de Costes. Clin Cardiovasc 1998, 16:27-34.
39. MSPS: Sistema Nacional de Salud, año 1997. Explotación de Bases del Conjunto Mínimo Básico de Datos Hospitalarios (CMBD) Madrid: Ministerio de Sanidad; 1997.
40. Lamas J, Alonso M, Saavedra J, Garcia-Trio G, Rionda M, Ameijeiras M: Costes de la diálisis crónica en un hospital. público: mitos y realidades. Nefrologia 2001, 21:283-294.
41. INE. Instituto Nacional de Estadística. Sociedad: Nivel, calidad y condiciones de vida. Indice de Precios de Consumo. [http://www.ine.es].
42. Oblikue Consulting Base de datos sanitarios eSalud. [http://www.oblikue. com/bddcostes/], [accessed November 12th, 2010].
43. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA: Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002, 63(10):920-930.
44. Oh PI, Lanctot KL, Mittmann N, Iskedjian M, Einarson T: Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ 2001, 4:137-156.
45. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002, 346(1):16-22, Erratum in: N Engl J Med 2002, 346(18):1424.
46. Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G: Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004, 7(5):569-584.
47. Palmer CS, Brunner E, Ruíz-Flores LG, Paez-Agraz F, Revicki DA: A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Res 2002, 33(6):572-580.
48. Almond S, O'Donnell O: Cost analysis of the treatment of schizophrenia in the UK: A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000, 17(4):383-389.
49. De Cock E, Miratvilles M, González-Juanatey JR, Azanza-Perea JR: Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura. Pharmacoecon Sp Res Art 2007, 4:97-107.
50. Farahati F, Boucher M, Moulton K, Williams R, Herrmann N, Silverman M, Skidmore B: Overview of atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology overview number 32]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007.
51. Whitehead SJ, Ali S: Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010, 96:5-21.
52. Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A: Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005, 8(1):10-23.
53. Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ: Utilities of the EQ-5D: transferable or not? Pharmacoeconomics 2009, 27(9):767-779.
54. Oliva-Moreno J, López-Bastida J, Osuna-Guerrero R, Montejo-González AL, Duque-González B: The costs of schizophrenia in Spain. Eur J Health Econ 2006, 7(3):182-188.